Introduction: CD44s, E-cadherin and β-catenin are cell adhesion molecules (CAMs) and appear to influence organ development, inflammation, cancer invasion and metastasis. We studied the expression of these CAMs in prostate cancer (PCa), high-grade prostatic intraepithelial neoplasia (HGPIN) and nodular adenomatous hyperplasia (NH). Materials and Methods: 135 paraffin blocks of radical prostatectomy specimens were assessed. CAMs were determined by immunohistochemistry. All sections included PCa, HGPIN and NH. The expression was semiquantitatively evaluated in three scores (1+, 2+, 3+). The markers’ immunopositivity was statistically investigated with Gleason score and TNM stage. Results and Conclusions: CD44s had score 3+ in 41.5, 46.7 and 37.8% of areas with NH, HGPIN and PCa, respectively. E-cadherin immunostaining was highly detected in 71.1, 78.5 and 63.0% of NH, HGPIN and PCa areas while β-catenin score 3+ was exclusively membranous in 80.7% of NH and nuclear/cytoplasmic in 70.4 and 48.9% of HGPIN and PCa areas. No marker related to the Gleason score (p = 0.352). CD44s and E-cadherin expression was inversely associated with TNM stage (p = 0.021 and p = 0.042, respectively); no such association was observed for β-catenin (p = 0.556). The decreased expression of CD44s and E-cadherin is probably associated with the invasive potential of PCa. The β-catenin staining pattern in neoplastic lesions, either preinvasive or invasive, differs from that in non-neoplastic prostate lesions.

Keywords:
Prostate, CD44s, E-cadherin, β-Catenin, Immunohistochemistry
1.
Morita N, Uemura H, Tsumatani K, Cho M, Hirao Y, Okajima E, Konishi N, Hiasa Y: E-cadherin and α-, β- and γ-catenin expression in prostate cancers: correlation with tumour invasion. J Cancer 1999;79:1879–1883.
2.
Ugolkov AV, Eisengart LJ, Luan CH, Yang XJ: Expression analysis of putative stem cell markers in human benign and malignant prostate. Prostate 2011;71:18–25.
3.
Takeichi M: The cadherins: cell-cell adhesion molecules controlling animal morphogenesis. Development 1998;102:639–655.
4.
Pignatelli M, Vessey CJ: Adhesion molecules: novel molecular tools in tumor pathology. Hum Pathol 1994;25:849–856.
5.
Shimoyama Y, Nagafuchi A, Fujita S, Gotoh M, Takeichi M, Tsukita S, Hirohashi S: Cadherin dysfunction in a human cancer cell line: possible involvement of loss of α-catenin expression in reduced cell-cell adhesiveness. Cancer Res 1992;52:5770–5774.
6.
Kemler R: From cadherins to catenins: cytoplasmic protein interaction and regulation of cell adhesion. Trends Genet 1993;9:317–321.
7.
Kallakury BVS, Sheehan CH, Ross JS: Co-downregulation of cell adhesion proteins α- and β-catenins, p120CTN, E-cadherin, and CD44 in prostatic adenocarcinomas. Hum Pathol 2001;32:849–855.
8.
Georgolios A, Batistatou A, Charalabopoulos A, Manopoulos L, Charalabopoulos K: The role of CD44 adhesion molecule in oral cavity cancer. Exp Oncol 2006;28:94–98.
9.
Stavropoulos NE, Filliadis I, Ioachim E, Michael M, Mermiga E, Hastazeris K, Nseyo UO: CD44 standard form expression as a predictor of progression in high-risk superficial bladder tumors. Int Urol Nephrol 2001;33:479–483.
10.
Liu J, Jiang G: CD44 and hematologic malignancies. Cell Mol Immunol 2006;3:359–365.
11.
Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, Reilly JG, Chandra D, Zhou J, Claypool K, Coghlan L, Tang DG: Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006;25:1696–1708.
12.
Jaggi M, Johansson SL, Baker JJ, Smith LM, Galich A, Balaji KC: Aberrant expression of E-cadherin and β-catenin in human prostate cancer. Urol Oncol 2005;23:402–406.
13.
Iczkowski KA: Cell adhesion molecule CD44: its functional roles in prostate cancer. Am J Transl Res 2001;3:1–7.
14.
Pontes J Jr, Srougi M, Borra PM, Dall’Oglio MF, Ribeiro-Filho LA, Leite KR: E-cadherin and β-catenin loss of expression related to bone metastasis in prostate cancer. Appl Immunohistochem Mol Morphol 2010;18:179–184.
15.
De Marzo AM, Knudsen B, Chan-Tack K, Epstein JI: E-cadherin expression as a marker of tumour aggressiveness in routinely processed radical prostatectomy specimens. Urology 1999;53:707–713.
16.
Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HFM, Oosterhof GON, Debruyne FMG, Schalken JA: Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994;54:3929–3933.
17.
Shiozaki H, Tahara H, Oka H, Miyama M, Kobayashi K, Tamura S, Iihara K: Expression of immunoreactive E-cadherin adhesion molecules in human cancers. Am J Pathol 1991;139:17–23.
18.
Aschida K, Terada T, Kitamura Y, Kaibara N: Expression of E-cadherin, α-catenin, β-catenin, and CD44 (standard and variant isoforms) in human cholangiocarcinoma: an immunohistochemical study. Hepatology 1998;27:977–982.
19.
Mansouri A, Spurr N, Goodfellow PN, Kemler R: Characterization and chromosomal localization of the gene encoding the human cell adhesion molecule uvomorulin. Differentiation 1988;38:67–71.
20.
Aaltomaa S, Lipponen P, Ala-Opas M, Kosma VM: Expression and prognostic value of CD44 standard and variant v3 and v6 isoforms in prostate cancer. Eur Urol 2001;39:138–144.
21.
Paradis V, Eschwege P, Loric S, Dumas F, Ba N, Benoit G, Jardin A, Bedossa P: De novo expression of CD44 in prostate carcinoma is correlated with systemic dissemination of prostate cancer. J Clin Pathol 1998;51:798–802.
22.
Haggman MJ, Macoska JA, Wojno KJ, Oesterling JE: The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues. J Urol 1997;158:12–22.
23.
Hlubek F, Jung A, Kotzor N, Kirchner T, Brabletz T: Expression of the invasion factor laminin γ2 in colorectal carcinomas is regulated by β-catenin. Cancer Res 2001;61:8089–8093.
24.
Woo DK, Kim HS, Lee HS, Kang YH, Yang HK, Kim WH: Altered expression and mutation of β-catenin gene in gastric carcinomas and cell lines. Int J Cancer 2001;95:108–113.
25.
Utsunomiya T, Doki Y, Takemoto H, Shiozaki H, Yano M, Sekimoto M, Tamura S, Yasuda T, Fujiwara Y, Monden M: Correlation of β-catenin and cyclin D1 expression in colon cancers. Oncology 2001;61:226–233.
26.
Yang F, Li X, Sharma M, Sasaki CY, Longo DL, Lim B, Sun Z: Linking β-catenin to androgen-signaling pathway. J Biol Chem 2002;277:11336–11344.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.